XML 29 R22.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Information

14. Segment Information

The Company operates under one reportable business segment to advance the development, manufacturing and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. The determination of a single reportable business segment is consistent with the consolidated financial information regularly provided to the Company’s CODM. All of the Company's long-term assets and operations are located in the United States, and the measure of segment assets is reported on the condensed consolidated balance sheets as total assets. The Company’s CODM is its Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance, including comparing actual results to budgets and forecasts to assess variances, identify trends, and guide strategic planning.

In addition to the significant expense categories included within the consolidated statements of operations, the below disaggregated amounts comprise significant research and development and general and administrative expenses. These expenses consist of (1) clinical, manufacturing and research contracts for research and development programs, (2) personnel-related expenses, including salaries, benefits and share-based compensation, (3) professional fees, including third-party costs for goods and services such as lab supplies and contract research, and legal and other professional expenses, and (4) facility and other overhead expenses, including depreciation, occupancy, travel, insurance and other costs. Depreciation and amortization expense is consistent with those presented in the condensed consolidated statements of cash flows.

 

 

 

For the Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

(in thousands)

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Research and development

 

 

 

 

 

 

 

 

 

 

 

 

  Clinical, development and licensing expenses

 

$

535

 

 

$

1,272

 

 

$

1,336

 

 

$

2,676

 

  Personnel related expenses

 

 

416

 

 

 

837

 

 

 

882

 

 

 

1,629

 

  Professional fees

 

 

128

 

 

 

316

 

 

 

346

 

 

 

582

 

  Facility and other overhead expenses

 

 

167

 

 

 

348

 

 

 

438

 

 

 

649

 

     Total research and development

 

 

1,246

 

 

 

2,773

 

 

 

3,002

 

 

 

5,536

 

General and administrative

 

 

 

 

 

 

 

 

 

 

 

 

  Personnel related expenses

 

 

965

 

 

 

700

 

 

 

1,949

 

 

 

1,348

 

  Professional expenses

 

 

397

 

 

 

1,130

 

 

 

2,003

 

 

 

2,300

 

  Facility and other overhead expenses

 

 

320

 

 

 

373

 

 

 

569

 

 

 

768

 

     Total general and administrative

 

$

1,682

 

 

$

2,203

 

 

$

4,521

 

 

$

4,416